The spectrum of molecular aberrations in myelodysplastic syndromes: In the shadow of acute myeloid leukemia

Haematologica

Volumn 92, Issue 6, 2007, Pages 723-727

  Steensma, David P ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BIOLOGICAL MARKER; CD135 ANTIGEN; DNA BINDING PROTEIN; JANUS KINASE 2; PROTEIN P53; STEM CELL FACTOR; TRANSCRIPTION FACTOR RUNX1;

ACUTE GRANULOCYTIC LEUKEMIA; CELL DIFFERENTIATION; CELL SURVIVAL; CHROMOSOME TRANSLOCATION; EDITORIAL; GENE AMPLIFICATION; GENE DELETION; GENE DUPLICATION; GENE MUTATION; GENE REARRANGEMENT; GENETIC DISORDER; HUMAN; MOLECULAR BIOLOGY; MYELODYSPLASTIC SYNDROME; ONCOGENE K RAS; ONCOGENE N RAS; POINT MUTATION; ACUTE DISEASE; APOPTOSIS; CELL PROLIFERATION; GENETICS; GENOMICS; METHODOLOGY; MYELOID LEUKEMIA; NOTE; PATHOLOGY;

ACUTE DISEASE; APOPTOSIS; CELL PROLIFERATION; GENOMICS; HUMANS; LEUKEMIA, MYELOID; MYELODYSPLASTIC SYNDROMES;

EID: 34347222913     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11471     Document Type: Editorial

References (31)

1. Frohling S, Scholl C, Gilliland DG, Levine RL. Genetics of myeloid malignancies: pathogenetic and clinical implications. J Clin Oncol 2005;23:6285-95.
2. Mrozek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood 2007;109:431-48.
3. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005;352:254-66.
4. Chen W, Rassidakis GZ, Medeiros LJ. Nucleophosmin gene mutations in acute myeloid leukemia. Arch Pathol Lab Med 2006;130:1687-92.
5. Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 2006;107:4011-20.
6. Gilliland DG, Griffin JD. Role of FLT3 in leukemia. Curr Opin Hematol 2002;9:274-81.
7. Look AT. Molecular pathogenesis of MDS. Hematology (Am Soc Hematol Educ Program) 2005:156-60.
8. Steensma DP, List AF. Genetic testing in the myelodysplastic syndromes: molecular insights into hematologic diversity. Mayo Clin Proc 2005;80:681-98.
9. Shin MO, Kajigaya S, Levin BC, Young NS. Mitochondrial DNA mutations in patients with myelodysplastic syndromes. Blood 2003;101:3118-25.
10. Fenaux P. Chromosome and molecular abnormalities in myelodysplastic syndromes. Int J Hematol 2001;73:429-37.
11. Boultwood J, Wainscoat JS. Clonality in the myelodysplastic syndromes. Int J Hematol 2001;73:411-5.
12. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88.
13. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006;355:1456-65.
14. Liu E, Hjelle B, Morgan R, Hecht F, Bishop JM. Mutations of the Kirsten-ras proto-oncogene in human preleukaemia. Nature 1987;330:186-8.
15. Thein SL, Oscier DG, Flint J, Wainscoat JS. Ha-ras hypervariable alleles in myelodysplasia. Nature 1986;321:84-5.
16. Hirai H, Kobayashi Y, Mano H, Hagiwara K, Maru Y, Omine M, et al. A point mutation at codon 13 of the N-ras oncogene in myelodysplastic syndrome. Nature 1987;327:430-2.
17. Bacher U, Haferlach T, Kern W, Haferlach C, Schnittger S. A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. Haematologica 2007:92:744-52.
18. Parker JE, Mufti GJ, Rasool F, Mijovic A, Devereux S, Pagliuca A. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood 2000;96:3932-8.
19. Shimazaki K, Ohshima K, Suzumiya J, Kawasaki C, Kikuchi M. Evaluation of apoptosis as a prognostic factor in myelodysplastic syndromes. Br J Haematol 2000;110:584-90.
20. Caudill JS, Sternberg AJ, Li CY, Tefferi A, Lasho TL, Steensma DP. C-terminal nucleophosmin mutations are uncommon in chronic myeloid disorders. Br J Haematol 2006;133:638-41.
21. Harada H, Harada Y, Kimura A. Implications of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome (MDS): future molecular therapeutic directions for MDS. Curr Cancer Drug Targets 2006;6:553-65.
22. Pedersen-Bjergaard J, Christiansen DH, Desta F, Andersen MK. Alternative genetic pathways and cooperating genetic abnormalities in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2006;20:1943-9.
23. Pedersen-Bjergaard J, Andersen MK, Christiansen DH, Nerlov C. Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood 2002;99:1909-12.
24. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-8.
25. Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007;356:459-68.
26. Tefferi A. JAK2 mutations in polycythemia vera: molecular mechanisms and clinical applications. N Engl J Med 2007;356:444-5.
27. Tefferi A. Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era. Hematology Am Soc Hematol Educ Program 2006:240-5.
28. Baldus CD, Tanner SM, Ruppert AS, Whitman SP, Archer KJ, Marcucci G, et al. BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. Blood 2003;102:1613-8.
29. Lacayo NJ, Meshinchi S, Kinnunen P, Yu R, Wang Y, Stuber CM, et al. Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes. Blood 2004;104:2646-54.
30. Miyazato A, Ueno S, Ohmine K, Ueda M, Yoshida K, Yamashita Y, et al. Identification of myelodysplastic syndrome-specific genes by DNA microarray analysis with purified hematopoietic stem cell fraction. Blood 2001;98:422-7.
31. Hofmann WK, de Vos S, Komor M, Hoelzer D, Wachsman W, Koeffler HP. Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow. Blood 2002;100:3553-60.